Histiocytoses: emerging neoplasia behind inflammation

被引:141
作者
Haroche, Julien [1 ]
Cohen-Aubart, Fleur [1 ]
Rollins, Barret J. [4 ]
Donadieu, Jean [5 ]
Charlotte, Frederic [2 ]
Idbaih, Ahmed [3 ]
Vaglio, Augusto [6 ]
Abdel-Wahab, Omar [7 ]
Emile, Jean-Francois [8 ,9 ,10 ]
Amoura, Zahir [1 ]
机构
[1] Hop La Pitie Salpetriere, Serv Med Interne 2, Ctr Natl Reference Malad Auto Immunes Syst Rares, Inst E3M, F-75013 Paris, France
[2] Hop La Pitie Salpetriere, AP HP, Serv Anatomocytopathol, Paris, France
[3] Hop La Pitie Salpetriere, AP HP, Serv Neurol Mazarin, Paris, France
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[5] Hop Trousseau, AP HP, Serv Hematol, Paris, France
[6] Univ Hosp, Nephrol Unit, Parma, Italy
[7] Mem Sloan Kettering Canc Ctr, Leukemia Serv, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[8] Ambroise Pare Hosp, AP HP, EA4340, Boulogne, France
[9] Ambroise Pare Hosp, AP HP, Dept Pathol, Boulogne, France
[10] Univ Versailles, Boulogne, France
关键词
LANGERHANS-CELL HISTIOCYTOSIS; ERDHEIM-CHESTER-DISEASE; ROSAI-DORFMAN-DISEASE; MASSIVE LYMPHADENOPATHY; SINUS HISTIOCYTOSIS; MONOCENTRIC SERIES; HIGH PREVALENCE; FOLLOW-UP; MUTATIONS; INVOLVEMENT;
D O I
10.1016/S1470-2045(17)30031-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Histiocytoses are disorders characterised by inflammation and the accumulation of cells derived from the monocyte and macrophage lineages, which results in tissue damage. Although they are often considered rare disorders with protean clinical manifestations, considerable advances in the understanding of their genetics have led to increased clinical recognition of these conditions, and fuelled further insights into their pathogenesis. In this Review, we describe insights into the cells of origin, molecular pathology, clinical features, and treatment strategies for some of the most common histiocytic disorders, including Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease. With the discovery of recurrent mutations affecting the mitogen-activated protein kinase and mTOR-AKT pathways in some of these histiocytoses, our understanding of these diseases has now evolved from the concept of a primary inflammatory condition to that of a clonal neoplastic disease. This understanding has led to the development of effective mechanism-based therapeutic strategies for patients with histiocytic diseases.
引用
收藏
页码:E113 / E125
页数:13
相关论文
共 107 条
  • [1] Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group
    Akkari, V
    Donadieu, J
    Piguet, C
    Bordigoni, P
    Michel, G
    Blanche, S
    Casanova, JL
    Thomas, C
    Vilmer, E
    Fischer, A
    Bertrand, Y
    [J]. BONE MARROW TRANSPLANTATION, 2003, 31 (12) : 1097 - 1103
  • [2] Erdheim-Chester disease: Case report, PCR-based analysis of clonality, and review of literature
    Al-Quran, S
    Reith, J
    Bradley, J
    Rimsza, L
    [J]. MODERN PATHOLOGY, 2002, 15 (06) : 666 - 672
  • [3] How I treat Langerhans cell histiocytosis
    Allen, Carl E.
    Ladisch, Stephan
    McClain, Kenneth L.
    [J]. BLOOD, 2015, 126 (01) : 26 - 35
  • [4] Cell-Specific Gene Expression in Langerhans Cell Histiocytosis Lesions Reveals a Distinct Profile Compared with Epidermal Langerhans Cells
    Allen, Carl E.
    Li, Liunan
    Peters, Tricia L.
    Leung, Hon-Chiu Eastwood
    Yu, Alexander
    Man, Tsz-Kwong
    Gurusiddappa, Sivashankarappa
    Phillips, Michelle T.
    Hicks, M. John
    Gaikwad, Amos
    Merad, Miriam
    McClain, Kenneth L.
    [J]. JOURNAL OF IMMUNOLOGY, 2010, 184 (08) : 4557 - 4567
  • [5] CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients
    Arnaud, Laurent
    Hervier, Baptiste
    Neel, Antoine
    Hamidou, Mohamed A.
    Kahn, Jean-Emmanuel
    Wechsler, Bertrand
    Perez-Pastor, Gemma
    Blomberg, Bjorn
    Fuzibet, Jean-Gabriel
    Dubourguet, Francois
    Marinho, Antonio
    Magnette, Catherine
    Noel, Violaine
    Pavic, Michel
    Casper, Jochen
    Beucher, Anne-Berangere
    Costedoat-Chalumeau, Nathalie
    Aaron, Laurent
    Salvatierra, Juan
    Graux, Carlos
    Cacoub, Patrice
    Delcey, Veronique
    Dechant, Claudia
    Bindi, Pascal
    Herbaut, Christiane
    Graziani, Giorgio
    Amoura, Zahir
    Haroche, Julien
    [J]. BLOOD, 2011, 117 (10) : 2778 - 2782
  • [6] 18F-Fluorodeoxyglucose-Positron Emission Tomography Scanning Is More Useful in Followup Than in the Initial Assessment of Patients With Erdheim-Chester Disease
    Arnaud, Laurent
    Malek, Zoulikha
    Archambaud, Frederique
    Kas, Aurelie
    Toledano, Dan
    Drier, Aurelie
    Zeitoun, Delphine
    Cluzel, Philippe
    Grenier, Philippe A.
    Chiras, Jacques
    Piette, Jean-Charles
    Amoura, Zahir
    Haroche, Julien
    [J]. ARTHRITIS AND RHEUMATISM, 2009, 60 (10): : 3128 - 3138
  • [7] Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease
    Aubart, Fleur Cohen
    Emile, Jean-Francois
    Maksud, Philippe
    Galanaud, Damien
    Cluzel, Philippe
    Benameur, Neila
    Aumaitre, Olivier
    Amoura, Zahir
    Haroche, Julien
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) : 150 - 153
  • [8] A Case of H Syndrome Showing Immunophenotye Similarities to Rosai-Dorfman Disease
    Avitan-Hersh, Emily
    Mandel, Hanna
    Indelman, Margarita
    Bar-Joseph, Gad
    Zlotogorski, Abraham
    Bergman, Reuven
    [J]. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2011, 33 (01) : 47 - 51
  • [9] Recurrent BRAF mutations in Langerhans cell histiocytosis
    Badalian-Very, Gayane
    Vergilio, Jo-Anne
    Degar, Barbara A.
    MacConaill, Laura E.
    Brandner, Barbara
    Calicchio, Monica L.
    Kuo, Frank C.
    Ligon, Azra H.
    Stevenson, Kristen E.
    Kehoe, Sarah M.
    Garraway, Levi A.
    Hahn, William C.
    Meyerson, Matthew
    Fleming, Mark D.
    Rollins, Barrett J.
    [J]. BLOOD, 2010, 116 (11) : 1919 - 1923
  • [10] BAILDAM EM, 1992, J ROY SOC MED, V85, P179